We have observed
3 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after November 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
COMPOSITION SUITABLE FOR USE AS A RELEASE-OPTIMIZED MATERIAL FOR NANOIMPRINT PROCESSES AND USES THEREOF
PHARMACEUTICAL COMPOSITION COMPRISING LEFLUNOMIDE
PHARMACEUTICAL TABLET COMPOSITION COMPRISING ELTROMBOPAG OLAMINE